A5071144743- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Cancer survivorship and care
- Brain Metastases and Treatment
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
- Glioma Diagnosis and Treatment
- Lung Cancer Research Studies
- Immune cells in cancer
- Childhood Cancer Survivors' Quality of Life
- Advanced Radiotherapy Techniques
- Colorectal Cancer Treatments and Studies
- Diversity and Career in Medicine
- Exercise and Physiological Responses
- Cancer Research and Treatments
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Management of metastatic bone disease
- Virus-based gene therapy research
- Ultrasound and Hyperthermia Applications
- Effects of Radiation Exposure
Memorial Sloan Kettering Cancer Center
2015-2025
Cornell University
2019-2025
Stanford University
2023-2025
Stanford Medicine
2024
Cancer Prevention Institute of California
2023-2024
Stanford Cancer Institute
2023-2024
Swim Across America
2019-2023
Weill Cornell Medicine
2021-2023
Palo Alto Institute
2023
Kettering University
2018-2022
Abstract Immunotherapy holds the potential to induce durable responses, but only a minority of patients currently respond. The etiologies primary and secondary resistance immunotherapy are multifaceted, deriving not from tumor intrinsic factors, also complex interplay between cancer its microenvironment. In addressing frontiers in clinical immunotherapy, we describe two categories approaches design novel drugs combination therapies: first involves direct modification tumor, while second...
Exercise has been shown to improve postischemia perfusion of normal tissues; we investigated whether these effects extend solid tumors. Estrogen receptor–negative (ER-, 4T1) and ER+ (E0771) tumor cells were implanted orthotopically into syngeneic mice (BALB/c, N = 11–12 per group) randomly assigned exercise or sedentary control. Tumor growth, perfusion, hypoxia, components the angiogenic apoptotic cascades assessed by MRI, immunohistochemistry, western blotting, quantitative polymerase chain...
Abstract Relatlimab and nivolumab combination immunotherapy improves progression-free survival over monotherapy in patients with unresectable advanced melanoma 1 . We investigated this regimen resectable clinical stage III or oligometastatic IV (NCT02519322). Patients received two neoadjuvant doses (nivolumab 480 mg relatlimab 160 intravenously every 4 weeks) followed by surgery, then ten of adjuvant therapy. The primary end point was pathologic complete response (pCR) rate 2 resulted 57%...
To analyze long-term outcomes after treatment discontinuation of anti-programmed death-1 (anti-PD-1) therapy in a cohort patients with melanoma the longest follow-up yet available to our knowledge, including majority treated outside clinical trial. We also assessed efficacy retreatment anti-PD-1 or without ipilimumab relapsing patients.We retrospectively analyzed all nonuveal, unresectable stage III/IV single-agent at Memorial Sloan Kettering from 2009-2018 who had discontinued and least 3...
Expanding the US Food and Drug Administration-approved indications for immune checkpoint inhibitors in patients with cancer has resulted therapeutic success immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1%-12% a high fatality rate relative to other irAEs. Lack standardized disease definitions accurate phenotyping leads syndrome misclassification impedes development evidence-based treatments translational research. The objective this study was develop...
Abstract Purpose: Programmed cell death receptor-1 (PD-1) inhibitors are frontline therapy in advanced melanoma. Severe immune-related adverse effects (irAEs) often require immunosuppressive treatment with glucocorticoids (GCCs), but GCC use and its correlation patient survival outcomes during anti–PD-1 monotherapy remains unclear. Experimental Design: In this multicenter retrospective analysis, patients treated between 2009 2019 detailed use, data were identified from five independent...
Photon involved-field radiotherapy (IFRT) is the standard-of-care for patients with leptomeningeal metastasis (LM) from solid tumors. We tested whether proton craniospinal irradiation (pCSI) encompassing entire CNS would result in superior progression-free survival (PFS) compared IFRT.
Adoptive cell therapy with autologous, ex vivo-expanded, tumor-infiltrating lymphocytes (TILs) is being investigated for treatment of solid tumors and has shown robust responses in clinical trials. Based on the encouraging efficacy, tolerable safety profile, advancements a central manufacturing process, lifileucel now first US Food Drug Administration (FDA)-approved TIL product. To this end, management delivery practice guidance needed to ensure successful integration modality into care....
Monoclonal antibodies (mAb) targeting PD-1/PD-L1 have revolutionized melanoma treatment, yet data regarding effectiveness and tolerability across age groups is limited. We sought to determine the impact of on overall survival (OS), progression-free (PFS), rates immune-mediated toxicities in patients treated with anti-PD-1/anti-PD-L1 mAb at two academic medical centers.We retrospectively collected all metastatic anti-PD-1/PD-L1 between May 2009 April 2015. used Kaplan-Meier Cox regression...
The purpose of this study is to investigate the effects exercise on cancer progression, metastasis, and underlying mechanisms in an orthotopic model murine prostate cancer. C57BL/6 male mice (6–8 wk age) were orthotopically injected with transgenic adenocarcinoma mouse C-1 cells (5 × 10 5 ) randomly assigned ( n = 28) or a non-intervention control 31) groups. group was given voluntary access wheel 24 h/day for duration study. Four per serially killed days 14, 31, 36; remaining 38 (exercise,...
Abstract Both the combination of nivolumab + ipilimumab and single‐agent anti‐ PD ‐1 immunotherapy have demonstrated survival benefit for patients with advanced melanoma. As has a high rate serious side effects, further analyses in randomized trials versus are needed to understand who benefits most from combination. Clinical laboratory values that were routinely collected studies may provide information on relative immunotherapy. To prioritize which clinical factors ultimately explore these...
Patients treated with immune checkpoint blockade (ICB) sometimes experience immune-related adverse events (irAEs), requiring immuno-suppressive drugs such as corticosteroids despite the possibility that immunosuppression may impair antitumor effects of ICB. Here, we address dilemma using for treatment irAEs induced by ICB augments neoantigen-specific CD8+ T cell responses, resulting in tumor regression. In our model, simultaneous, but not late, administration impaired responses reduction...
Peripheral blood LAG + CD8 T cells are more commonly identified in immunotherapy-treated patients with cancer who have less favorable outcomes.
With an increasing number of patients eligible for immune checkpoint inhibitors, the incidence immune-related adverse events (irAEs) is on rise. Dermatologic (D-irAEs) are most common and earliest to manifest, often with important downstream consequences patient. Current guidelines lack clarity in terms diagnostic criteria D-irAEs. The goal this project better define D-irAE purposes identification, diagnosis, future study group diseases.The objectives were develop consensus guidance approach...
Abstract Pathologic angiogenesis creates an abnormal microenvironment in solid tumors, characterized by elevated interstitial fluid pressure (IFP) and hypoxia. Emerging theories suggest that judicious downregulation of proangiogenic signaling pathways may transiently “normalize” the vascular bed, making it more suitable for drug delivery radiotherapy. In this work, we investigate role pazopanib, a small-molecule inhibitor endothelial growth factor (VEGF) platelet-derived (PDGF) receptors, on...
Pneumonitis related to immune checkpoint blockade is uncommon but can be severe, fatal or chronic. Steroids are first-line treatment, however, some patients refractory become resistant steroids. Like many immune-related adverse events, little known regarding the outcomes and optimal management of in whom steroids ineffective.We performed a single-center retrospective cohort study at high-volume tertiary cancer center evaluate clinical course, strategies treated for pneumonitis with...